87 related articles for article (PubMed ID: 21371237)
21. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
22. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.
Nguyen HT; Duc NB; Shrivastava R; Tran TH; Nguyen TA; Thang PH; McNicholl JM; Leelawiwat W; Chonwattana W; Sidibe K; Fujita M; Luu CM; Kakkar R; Bennett DE; Kaplan J; Cosimi L; Wolfe MI
Antivir Ther; 2008; 13 Suppl 2():115-21. PubMed ID: 18575200
[TBL] [Abstract][Full Text] [Related]
23. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
[TBL] [Abstract][Full Text] [Related]
24. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
[TBL] [Abstract][Full Text] [Related]
26. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
Charpentier C; Gody JC; Tisserand P; Matta M; Péré H; Fournier J; Mbitikon O; Bélec L
Antivir Ther; 2011; 16(8):1347-50. PubMed ID: 22155917
[TBL] [Abstract][Full Text] [Related]
27. Documented prevalence of HIV type 1 antiretroviral transmitted drug resistance in Ireland from 2004 to 2008.
De Gascun CF; Waters A; Regan C; O'Halloran J; Farrell G; Coughlan S; Bergin C; Powderly WG; Hall WW
AIDS Res Hum Retroviruses; 2012 Mar; 28(3):276-81. PubMed ID: 21770812
[TBL] [Abstract][Full Text] [Related]
28. Transmitted HIV type 1 drug resistance in newly diagnosed Cuban patients.
Machado LY; Dubed M; Díaz H; Ruiz N; Romay D; Váldes N; Blanco M; Silva E
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):411-4. PubMed ID: 22985307
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of drug resistance mutations in the human immunodeficiency virus reverse transcriptase gene in patients who are non-responsive, responsive and naive to antiretroviral therapy.
Misbah M; Roy G; Shahid M; Nag N; Kumar S; Husain M
Arch Virol; 2016 May; 161(5):1101-13. PubMed ID: 26801790
[TBL] [Abstract][Full Text] [Related]
30. Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.
Cahn P; Altclas J; Martins M; Losso M; Cassetti I; Cooper DA; Cox S
HIV Med; 2011 Jul; 12(6):334-42. PubMed ID: 21054750
[TBL] [Abstract][Full Text] [Related]
31. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1.
Turner D; Brenner B; Wainberg MA
J Antimicrob Chemother; 2004 Jan; 53(1):53-7. PubMed ID: 14645322
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004.
Babic DZ; Zelnikar M; Seme K; Vandamme AM; Snoeck J; Tomazic J; Vidmar L; Karner P; Poljak M
Virus Res; 2006 Jun; 118(1-2):156-63. PubMed ID: 16417938
[TBL] [Abstract][Full Text] [Related]
34. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom.
; ;
AIDS; 2007 May; 21(8):1035-9. PubMed ID: 17457098
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
Nishizawa M; Matsuda M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
PLoS One; 2015; 10(9):e0135941. PubMed ID: 26360259
[TBL] [Abstract][Full Text] [Related]
36. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.
Jakobsen MR; Tolstrup M; Søgaard OS; Jørgensen LB; Gorry PR; Laursen A; Ostergaard L
Clin Infect Dis; 2010 Feb; 50(4):566-73. PubMed ID: 20085464
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
[TBL] [Abstract][Full Text] [Related]
38. 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
Alteri C; Santoro MM; Abbate I; Rozera G; Bruselles A; Bartolini B; Gori C; Forbici F; Orchi N; Tozzi V; Palamara G; Antinori A; Narciso P; Girardi E; Svicher V; Ceccherini-Silberstein F; Capobianchi MR; Perno CF
J Antimicrob Chemother; 2011 Nov; 66(11):2615-23. PubMed ID: 21890537
[TBL] [Abstract][Full Text] [Related]
39. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
[TBL] [Abstract][Full Text] [Related]
40. Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.
Mohamed S; Ravet S; Camus C; Khiri H; Olive D; Halfon P
J Med Virol; 2014 Mar; 86(3):394-403. PubMed ID: 24248806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
